Pharmacologically active guanidine compounds as H-2 histamine receptor inhibitors
AssigneeSmith Kline & French Laboratories Limited
InventorsGraham John Durant, John Colin Emmett, Charon Robin Ganellin
Life of this patent
Estimating the term…
Abstract
The compounds are substituted thioalkyl-, aminoalkyl-, and oxyalkyl-guanidines which are inhibitors of histamine activity.
Claims16
A pharmaceutical composition to inhibit H-2 histamine receptors comprising a pharmaceutical carrier and in an effective amount to inhibit said receptors a heterocyclic compound of the formula:
- ##STR15## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a thiazole, isothiazole, oxazole or isoxazole ring;
- X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR16## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen;
- k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4;
- Y is oxygen, sulphur or NH;
- E is NR.sub.2 ;
- R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl;
- and
- R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof.
A method of inhibiting H-2 histamine receptors which comprises administering to an animal in need of inhibition of said receptors in an effective amount to inhibit said receptors a heterocyclic compound of the formula:
- ##STR17## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a thiazole, isothiazole, oxazole or isoxazole ring;
- X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR18## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen;
- k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4;
- Y is oxygen, sulphur or NH;
- E is NR.sub.2 ;
- R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl;
- and
- R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof.
A method of inhibiting gastric acid secretion which comprises administering to an animal in need thereof in an effective amount to inhibit gastric acid secretion a heterocyclic compound of the formula:
- ##STR19## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a thiazole, isothiazole, oxazole or isoxazole ring;
- X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR20## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen;
- k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4;
- Y is oxygen, sulphur or NH;
- E is NR.sub.2 ;
- R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl;
- and
- R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof.
Dependencies are inferred from the claim text.